Bausch Health Companies (TSE:BHC) has released an update.
Bausch Health Companies Inc. and its division Salix Pharmaceuticals have announced updates on their ongoing litigation with Norwich Pharmaceuticals over the drug XIFAXAN. They are awaiting a decision on a potential rehearing after recent appeals, and facing a new challenge as Norwich seeks FDA approval for a generic version of the medication. Bausch Health is preparing to defend its patents vigorously, which could delay FDA approval of Norwich’s application.
For further insights into TSE:BHC stock, check out TipRanks’ Stock Analysis page.
